A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.


Updates from The Motley Fool

Latest updates on Seattle Genetics from Fool.com.  The Fool has written over 100 articles on Seattle Genetics.
3 Stocks We're Buying Again

Image source: Getty Images. Searching for your next investment can be difficult. Too often invest...

Last Week's Best Healthcare ETF

Image by Pictures of Money, Flickr Creative Commons. The healthcare space ended 2015 with a bit o...

Biotech Bad News Buys

It's pretty common to see a biotech tank on any given day, so when three companies dropped substa...



Stock Performance

View Interactive SGEN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Seattle Genetics.
Current Price: $66.93
Prev Close: $65.09
Open: $65.00
Bid: $61.27
Ask: $73.50
Day's Range: $64.50 - $67.07
52wk Range: $26.02 - $75.36
Volume: 714,142
Avg Vol 1,539,161
Market Cap: $9B
P/E (ttm): -83.45
EPS (ttm): ($0.78)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Seattle Genetics.
CAPS Rating 3 out of 5
 
463 Outperform
33 Underperform
CAPS All Stars
 
95 Outperform
11 Underperform

How do you think Seattle Genetics will perform against the market?



You pick for Seattle Genetics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Clay B. Siegall, CEO

86% Approve

Based on 20 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Seattle Genetics.

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers